上腔静脉切除在局部晚期胸腺上皮肿瘤扩大胸腺切除术中的结局与安全性分析
多因素分析显示胸腺癌和上腔静脉切除为不良预后因素,但上腔静脉切除组与未切除组的总生存和无进展生存无显著差异。结论认为上腔静脉切除安全有效,不影响生存和复发。
要点
- III-IVa期胸腺上皮肿瘤中上腔静脉切除占17.9%,手术安全可行。
- 上腔静脉切除组与未切除组OS(P=.28)和PFS(P=.32)无显著差异。
- 胸腺癌和上腔静脉切除是多因素分析中的不良预后因素。
核心结论
- 上腔静脉切除是恢复静脉系统连续性的安全有效方法,似乎不影响生存和疾病复发。
- 该手术方式允许对局部晚期胸腺上皮肿瘤实现根治性切除,甚至在新辅助化疗后。
研究设计与样本
- 回顾性研究,遵循STROBE方法学,纳入1998年1月至2019年4月78例Masaoka-Koga III-IVa期胸腺上皮肿瘤扩大胸腺切除术患者。
- 采用Kaplan-Meier法计算无进展生存和总生存,并行后向逐步Cox回归多因素分析。
主要发现
- 多因素分析中,胸腺癌(HR 2.26;95%CI 1.82-6.18;P=.038)和上腔静脉切除(HR 1.89;95%CI 1.11-3.96;P=.041)为不良预后因素。
- 上腔静脉切除患者的中位OS为50个月(范围5-207),中位PFS为31个月(范围5-151)。
- 上腔静脉切除组与未切除组OS(P=.28)和PFS(P=.32)无显著差异。
临床怎么用
- 对于III-IVa期胸腺上皮肿瘤侵犯上腔静脉者,可考虑行上腔静脉切除以达根治性切除。
- 上腔静脉切除未显著影响生存和复发,但胸腺癌和上腔静脉切除提示预后较差,需加强随访。
局限性
- 单中心经验,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In stage III to IVa thymic epithelial tumors (TETs), infiltration of the superior vena cava (SVC) is not rare. The extent of SVC resection depends on the width of the area of neoplastic invasion. Our article aims to evaluate the safety and long-term outcomes of extended thymectomy for TETs with SVC resection compared with advanced-stage TETs patients without SVC resection. METHODS: Retrospective review of the experience on patients who underwent extended thymectomy for TETs in the last 20 years, according to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) methodology. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. A backward stepwise Cox regression multivariate analysis was performed to determine factors associated with long-term outcomes. RESULTS: A total of 78 patients underwent surgery for advanced-stage TETs (Masaoka-Koga stages III-IVa) from January 1998 to April 2019. Fourteen (17.9%) underwent thymectomy with resection of SVC. Presence of a thymic carcinoma (hazard ratio , 2.26; 95% confidence interval, 1.82-6.18; P = .038) and the SVC resection (hazard ratio, 1.89; 95% confidence interval, 1.11-3.96; P = .041) were adverse prognostic factors at multivariate analysis. The median OS and the PFS of all SVC resected patients were 50 (range, 5-207) months and 31 (range, 5-151) months, respectively. There was no significant difference in OS (P = .28) and PFS (P = .32) between SVC-resected and non-SVC-resected patients. CONCLUSIONS: SVC resection is a safe and effective procedure to restore the venous system continuity and does not seem to affect survival and disease recurrence. This surgical approach allows radical resection of locally advanced TETs, even after neoadjuvant chemotherapy.
引用
- Bertolaccini L, Prisciandaro E, Galetta D, et al. Outcomes and Safety Analysis in Superior Vena Cava Resection for Extended Thymic Epithelial Tumors. Ann Thorac Surg. 2020. PMID: 33068543. doi:10.1016/j.athoracsur.2020.07.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。